Arrowhead Pharmaceuticals, Inc.
ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
Last updated:
Abstract:
The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
Status:
Application
Type:
Utility
Filling date:
24 Jun 2019
Issue date:
24 Oct 2019